ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 0401

Item Reduction for the Assessment of Systemic Sclerosis-associated RAynaud’s Phenomenon (ASRAP) Questionnaire Using Data from the International Multicentre ASRAP Validation Study

John Pauling1, Lan Yu2, Christopher Denton3, Tracy Frech4, Ariane Herrick5, Laura Hummers6, Lesley Ann Saketkoo7, Ami Shah8, Dinesh Khanna9 and Robyn Domsic2, 1Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom, 2University of Pittsburgh, Pittsburgh, PA, 3University College London Division of Medicine, Centre for Rheumatology and Connective Tissue Diseases, London, United Kingdom, 4University of Utah, Salt Lake City, UT, 5University of Manchester, Salford, United Kingdom, 6Johns Hopkins Univerisity, Baltimore, MD, 7University Medical Center - Comprehensive Pulmonary Hypertension Center, New Orleans, LA, 8Johns Hopkins Rheumatology, Baltimore, MD, 9University of Michigan, Ann Arbor, MI

Meeting: ACR Convergence 2021

Keywords: Biostatistics, Outcome measures, Patient reported outcomes, Raynaud's phenomenon, Systemic sclerosis

  • Tweet
  • Email
  • Print
Session Information

Date: Saturday, November 6, 2021

Session Title: Systemic Sclerosis & Related Disorders – Clinical Poster I (0387–0413)

Session Type: Poster Session A

Session Time: 8:30AM-10:30AM

Background/Purpose: The Assessment of Systemic sclerosis-associated RAynaud’s Phenomenon (ASRAP) questionnaire is a novel patient-reported outcome (PRO) instrument devised to assess the severity and impact of SSc-RP. We report a data driven approach to item reduction of the preliminary 39-item questionnaire.

Methods: The international multicentre ASRAP validation study enrolled SSc patients with RP from English speaking UK (n=3) and US (n=4) SSc centres during 2 consecutive winters (2019-2021). All participants completed a 39-item ASRAP questionnaire. Pooled data was used to assess dimensionality, before splitting the cohort to facilitate exploratory and confirmatory factor analyses (CFA). Items with low factor loadings < 0.5 and/or low item discrimination parameter estimates (α< 1.5) were considered for removal. Local dependency (LD) marginal Chi square analyses identified redundant items. Goodness-of-fitness testing examined the extent to which observed data fitted the item response model. Finally, differential item functioning (DIF) explored extent to which each item may measuredifferent concepts according to geographic enrolment (UK versus US sites). At each step, items were retained if content validity considered them essential.

Results: A total of 438 SSc subjects were enrolled at UK (n=238) and US (n=200) sites, with adequate data for analysis on 421 subjects. Eigenvalues for uni- and bi-dimensional options were 21.577 and 3.08 respectively. A single factor solution provided the best-fitting model with factor loadings for the majority of factors ~0.8. Three items were removed owing to lower factor loadings (0.415-0.443). CFA revealed a Root Mean Square Error of Approximation of 0.114, a Standardized Root Mean Square Residual of 0.083 and a Confirmatory Factor Index of 0.917; each indicating excellent fit. Four low scoring Item Discrimination Parameter estimates (Figure 1) were identified (alpha scores of 1.04-1.25), leading to removal of one item (the remainder having already been removed). Only 14 potentially redundant pairings were identified using LD marginal chi square ( >10 indicates redundancy), which led to the removal of a further 6 items (Figure 2). Model fit analyses identified 3 problematic items; one of which was removed, one retained due to content validity and the other already removed). Finally, DIF identified 3 items which differed due to geographic location (2 already removed) and led to removal of an item (Figure 3).

Conclusion: We report a data driven approach (focussed on item response theory) to removing problematic or redundant items from the provisional ASRAP item bank. This has facilitated item reduction to a 27-item PRO instrument that will undergo psychometric testing and other tests of reliability and construct validity.


Disclosures: J. Pauling, None; L. Yu, None; C. Denton, Acceleron, 2, 6, Actelion, 2, 6, Arxx Therapeutics, 2, 6, Boehringer Ingelheim, 2, 6, Bristol-Myers Squibb, 2, 6, Corbus, 2, 6, CSL Behring, 2, 6, Galapagos NV, 2, 6, GlaxoSmithKline, 2, 6, Horizon, 2, 6, Inventiva, 2, 6, Roche, 2, 6, Sanofi, 2, 6, Servier, 2; T. Frech, None; A. Herrick, None; L. Hummers, Boerhinger Ingelheim, 1, 5, Corbus Pharmaceuticals, 1, 5, Cumberland Pharmaceuticals, 5, Kadmon Corporation, 5, Medpace, 5; L. Saketkoo, None; A. Shah, None; D. Khanna, AbbVie, 2, Acceleron, 2, Actelion, 2, Amgen, 2, Bayer, 2, 5, Boehringer Ingelheim, 2, Bristol-Myers Squibb, 5, CiviBioPharma/Eicos Sciences, Inc, 12, Leadership/Equity position (Chief Medical Officer), Corbus, 2, CSL Behring, 2, Eicos Sciences, Inc, 11, Galapagos NV, 2, Genentech/Roche, 2, Gilead, 2, GlaxoSmithKline, 2, Horizon Therapeutics, 2, 5, Immune Tolerance Network, 5, Merck Sharp & Dohme, 2, Mitsubishi Tanabe Pharma, 2, National Institutes of Health, 5, Pfizer, 5, Sanofi-Aventis, 2, United Therapeutics, 2, Prometheus, 2, Theraly, 2, AstraZeneca, 2; R. Domsic, None.

To cite this abstract in AMA style:

Pauling J, Yu L, Denton C, Frech T, Herrick A, Hummers L, Saketkoo L, Shah A, Khanna D, Domsic R. Item Reduction for the Assessment of Systemic Sclerosis-associated RAynaud’s Phenomenon (ASRAP) Questionnaire Using Data from the International Multicentre ASRAP Validation Study [abstract]. Arthritis Rheumatol. 2021; 73 (suppl 9). https://acrabstracts.org/abstract/item-reduction-for-the-assessment-of-systemic-sclerosis-associated-raynauds-phenomenon-asrap-questionnaire-using-data-from-the-international-multicentre-asrap-validation-study/. Accessed January 30, 2023.
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2021

ACR Meeting Abstracts - https://acrabstracts.org/abstract/item-reduction-for-the-assessment-of-systemic-sclerosis-associated-raynauds-phenomenon-asrap-questionnaire-using-data-from-the-international-multicentre-asrap-validation-study/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2023 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences